Matches in SemOpenAlex for { <https://semopenalex.org/work/W2595759017> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W2595759017 abstract "e15164 Background: Unresectable locally advanced adenocarcinoma (AGC) of the stomach is associated with poor prognosis due to the lack of effective treatment. Neoadjuvant chemotherapy (NAC) has drawn more attention to the treatment of locally AGC in the current multidisciplinary treatment model. Paclitaxel and capecitabine (PX) has been used in palliative setting with good response rates but its role in a neoadjuvant setting is not well established. This phase II study was performed to evaluate the efficacy and safety of neoadjuvant PX chemotherapy in patients with unresectable locally AGC. Methods: Patients with AGC, clinically unresectable because of local invasion and/ or conglomerated regional lymph nodes (station 7, 8, and 9) metastasis on based on laparoscopic staging, were enrolled. PX consisted of paclitaxel 175 mg/m 2 i.v. on day 1, and capecitabine 835 mg/m 2 twice daily p.o. on days 1–14 every 21 days. After three cycles of NAC, patients with clinically resectable AGC underwent surgical resection. Results: This trial was stopped for poor accrual after 18 patients were enrolled; 50% patients had tumors located in the proximal third of the stomach. Seventeen patients finished three cycles of chemotherapy. The overall response rate was 41.2% (7/17 cases), of which 71.4% (10/14 cases) metabolic response. Fourteen (77.8%) of the 18 patients enrolled underwent surgery, and 12 (85.7%) had an R0 resection. Pathological complete response was observed in one (7.1%) of patients. Toxicity was mild to moderate and there were no treatment-related deaths and no major surgical complications. With a median follow-up of 28.6 months (range 6.4-38.4 months), the 2-year survival rate for all patients was 71.1%. Subgroup analysis found R0 resection (35.7 months vs. 20.6 months, P= 0.005) and patients with pathologic N downstaging (P < 0.001) to have improved overall survival. Conclusions: Neoadjuvant chemotherapy with PX shows promising results in unresectable locally AGC patients without increased morbidity and mortality. Neoadjuvant PX may permit a larger chance of curative resection in unresectable locally AGC patients." @default.
- W2595759017 created "2017-03-23" @default.
- W2595759017 creator A5012148094 @default.
- W2595759017 creator A5014474281 @default.
- W2595759017 creator A5053600900 @default.
- W2595759017 creator A5064153008 @default.
- W2595759017 creator A5075108989 @default.
- W2595759017 creator A5076585994 @default.
- W2595759017 creator A5083661343 @default.
- W2595759017 creator A5088316493 @default.
- W2595759017 date "2013-05-20" @default.
- W2595759017 modified "2023-09-26" @default.
- W2595759017 title "Phase II study of paclitaxel and capecitabine (PX) combination as neoadjuvant chemotherapy for unresectable locally advanced gastric cancer." @default.
- W2595759017 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.e15164" @default.
- W2595759017 hasPublicationYear "2013" @default.
- W2595759017 type Work @default.
- W2595759017 sameAs 2595759017 @default.
- W2595759017 citedByCount "0" @default.
- W2595759017 crossrefType "journal-article" @default.
- W2595759017 hasAuthorship W2595759017A5012148094 @default.
- W2595759017 hasAuthorship W2595759017A5014474281 @default.
- W2595759017 hasAuthorship W2595759017A5053600900 @default.
- W2595759017 hasAuthorship W2595759017A5064153008 @default.
- W2595759017 hasAuthorship W2595759017A5075108989 @default.
- W2595759017 hasAuthorship W2595759017A5076585994 @default.
- W2595759017 hasAuthorship W2595759017A5083661343 @default.
- W2595759017 hasAuthorship W2595759017A5088316493 @default.
- W2595759017 hasConcept C121608353 @default.
- W2595759017 hasConcept C126322002 @default.
- W2595759017 hasConcept C143998085 @default.
- W2595759017 hasConcept C2776694085 @default.
- W2595759017 hasConcept C2777292972 @default.
- W2595759017 hasConcept C2777909004 @default.
- W2595759017 hasConcept C2778292576 @default.
- W2595759017 hasConcept C31760486 @default.
- W2595759017 hasConcept C526805850 @default.
- W2595759017 hasConcept C530470458 @default.
- W2595759017 hasConcept C71924100 @default.
- W2595759017 hasConceptScore W2595759017C121608353 @default.
- W2595759017 hasConceptScore W2595759017C126322002 @default.
- W2595759017 hasConceptScore W2595759017C143998085 @default.
- W2595759017 hasConceptScore W2595759017C2776694085 @default.
- W2595759017 hasConceptScore W2595759017C2777292972 @default.
- W2595759017 hasConceptScore W2595759017C2777909004 @default.
- W2595759017 hasConceptScore W2595759017C2778292576 @default.
- W2595759017 hasConceptScore W2595759017C31760486 @default.
- W2595759017 hasConceptScore W2595759017C526805850 @default.
- W2595759017 hasConceptScore W2595759017C530470458 @default.
- W2595759017 hasConceptScore W2595759017C71924100 @default.
- W2595759017 hasLocation W25957590171 @default.
- W2595759017 hasOpenAccess W2595759017 @default.
- W2595759017 hasPrimaryLocation W25957590171 @default.
- W2595759017 isParatext "false" @default.
- W2595759017 isRetracted "false" @default.
- W2595759017 magId "2595759017" @default.
- W2595759017 workType "article" @default.